Special 5/2013

  • Biocapital

    In this issue:

    Good biocapital access – for a few

    In an era when payers are increasingly also looking at the economic benefits a new therapeutic has to offer, biotechs have to prove not only safety and efficacy to regulators, but cost-effectiveness to reimbursers as well. Both factors are subject to due dilligence when it comes time to apply for financing. That's why convincing investors of the value of product portfolios – which are most often developed by biotech innovators – has become a complex task. Market forecasts by Prime Therapeutics/Blue Cross-Blue Shield predict specialty drugs will account for 50% of all drug costs by 2018 (up from 20% in 2009). But the most current Global Biotech Report released by Ernst & Young at the end of April says despite that promising future, just a few large biotechs are benefiting from financing.

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/spezial/2013/5/pos/1.html?cHash=bfd90e2d54056358af1b4a091bcb4f71&sort=asc

Kurszettel

Alle Kurse

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR349.3%
  • SANTHERA (CH)69.50 CHF114.8%
  • ADDEX (CH)4.21 CHF92.2%

FLOP

  • MERCK KGAA (D)63.45 EUR-51.0%
  • THROMBOGENICS (B)8.55 EUR-47.3%
  • VERONA PHARMA (UK)1.12 GBP-46.2%

TOP

  • SANTHERA (CH)69.50 CHF3410.1%
  • GW PHARMACEUTICALS (UK)415.25 GBP756.2%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.5%

No liability assumed, Date: 21.07.2014